Tag: Pharmacology

Sourav Pal, Pharmacology, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Sourav Pal, Pharmacology, Best Innovator Award

Asst. Prof. Sourav Pal: Assistant Professor at Department of Pharmacology, Seacom Pharmacy College, Jaladhulagori, Sankrail, Howrah, West Bengal, 711302, India

Sourav Pal is a dedicated academic and researcher in the field of Pharmaceutical Sciences with a focus on Pharmacology. He currently serves as an Assistant Professor at Seacom Pharmacy College, Howrah, since July 2024, where he actively contributes to teaching, research, and curriculum development. Sourav’s academic journey culminated in a Master’s in Pharmacy (Pharmacology) from Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences in 2022, achieving a commendable CGPA of 9.58. His research is centered on exploring the pharmacological and therapeutic potential of plant-based compounds, as well as assessing the neurobehavioral and toxicological effects of various substances. He is also passionate about the integration of artificial intelligence (AI) and machine learning in pharmaceutical research, particularly in drug design and delivery systems.

Online Profiles

Education

Sourav Pal’s academic foundation is rooted in his profound interest in the pharmaceutical sciences. He earned his Master’s in Pharmacy (Pharmacology) from Calcutta Institute of Pharmaceutical Technology & Allied Health Sciences in 2022, where he stood out with a CGPA of 9.58. Prior to that, he completed his Bachelor’s in Pharmacy with an outstanding CGPA of 8.90 in 2020. His academic pursuits began with his Higher Secondary education in 2016 at Bangalpur U.C High School, achieving 73%, followed by his Secondary Education in 2014, where he scored 76.5%. Throughout his academic career, Sourav has remained dedicated to enhancing his knowledge in both theoretical and practical aspects of pharmacology.

Research Focus

Sourav’s research primarily investigates the pharmacological properties of medicinal plants and synthetic compounds, emphasizing their neuroprotective, antioxidant, and antimicrobial activities. His recent studies focus on the toxicological effects of plant extracts, such as Swietenia mahagoni and Mimosa pudica, on animal models, exploring their potential to treat neurological diseases, including Alzheimer’s and Parkinson’s. He is particularly interested in the molecular mechanisms underlying neurodegeneration and the role of heavy metals and oxidative stress in the progression of neurological diseases. Sourav also explores advanced drug delivery systems, particularly those involving nanoformulations, to improve the efficacy and safety profiles of pharmaceutical compounds.

Experience

Sourav’s career has spanned both teaching and research, with a focus on integrating advanced pharmacological concepts into practical learning experiences. As an Assistant Professor at Seacom Pharmacy College, Howrah, he actively engages in curriculum development, student mentoring, and research supervision. Before this, he worked as a Lecturer/Assistant Professor at P.G. Institute of Medical Sciences, Chandrakona Town, where he contributed significantly to the academic growth of students and led research projects on pharmacological evaluations of herbal extracts. Sourav has built a reputation for his problem-solving skills, innovative approach to teaching, and his ability to identify and nurture the strengths of his students.

Research Timeline & Activities

Sourav’s research timeline includes multiple projects that span various aspects of pharmacology and toxicology. His earlier projects, including his work on Sechium edule (chayote), involved assessing the antihyperlipidemic effects and exploring its potential to mitigate cardiovascular conditions. More recently, he has supervised research on the antioxidant and neuroprotective effects of Swietenia mahagoni in zebrafish models. Sourav has mentored several graduate students, guiding them through experimental methodologies, data analysis, and scientific writing. Additionally, he actively participates in international and national conferences, webinars, and faculty development programs (FDPs), particularly those focusing on AI, machine learning, and advanced research methodologies.

Awards & Honors

  • Life Membership in the Association of Pharmaceutical Teachers of India (APTI) (ID: WB/LM-367, 2023)

  • Reviewer for prestigious international journals such as Molecular Neurobiology, Biochemical Genetics, and The Journal of Basic and Applied Zoology.

  • Registered Pharmacist (A-24986) with the West Bengal Pharmacy Council

  • Best Research Paper Award at various national and international conferences on drug discovery and pharmacology.

  • Recognized for contributions to pharmaceutical education and research through awards from academic institutions and research organizations.

Top Noted Publication

Sourav has published over 15 research papers, covering a wide range of topics in pharmacology, toxicology, and plant-based therapeutics. Notable among them are:

1. Antioxidants in Cardiovascular Disease: Molecular Interaction and Therapeutic Implications

  • Book Chapter: Antioxidants: Nature’s Defense Against Disease

  • Publication Year: 2025

  • DOI: 10.1002/9781394270576.ch4

  • ISBN: 9781394270576, 9781394270552

  • Contributors: Firdous, S.M.; Pal, S.

  • Source: Scopus – Elsevier

  • Summary: This chapter delves into the molecular interactions of antioxidants within the cardiovascular system, emphasizing their therapeutic potential in combating cardiovascular diseases (CVD). It explores the role of oxidative stress in the pathogenesis of CVD and the protective actions of antioxidants at a molecular level, presenting new therapeutic strategies for CVD management.

2. Antioxidants in Inflammatory Diseases

  • Book Chapter: Antioxidants: Nature’s Defense Against Disease

  • Publication Year: 2025

  • DOI: 10.1002/9781394270576.ch3

  • ISBN: 9781394270576, 9781394270552

  • Contributors: Firdous, S.M.; Pal, S.; Mandal, S.; Sindhu, R.K.

  • Source: Scopus – Elsevier

  • Summary: This chapter investigates the role of antioxidants in the prevention and treatment of inflammatory diseases. The text covers molecular mechanisms by which antioxidants mitigate inflammatory responses and discusses their clinical application in inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and other chronic inflammatory disorders.

3. Neurobehavioral Effects and Brain GFAP Modulation by Mimosa pudica Extract in Zebrafish Exposed to Zinc Oxide Nanoparticles

  • Journal Article: The Journal of Basic and Applied Zoology

  • Publication Date: 17th August 2025

  • DOI: 10.1186/s41936-025-00484-z

  • Contributors: Sourav Pal; Brisanka Tarafder; Debashish Dey; Sayed Mohammed Firdous

  • Source: Crossref

  • Summary: This study assesses the neurobehavioral effects of Mimosa pudica extract in zebrafish exposed to zinc oxide nanoparticles. The research focuses on the modulation of brain glial fibrillary acidic protein (GFAP), which serves as a marker for neuroinflammation. The findings support the neuroprotective potential of Mimosa pudica against neurotoxicity induced by nanoparticles, offering insights into natural products for neurological protection.

4. Helicobacter pylori in Peptic Ulcer Disease: Pathogenesis, Gastric Microbiome, and Innovative Therapies

  • Journal Article: Bulletin of the National Research Centre

  • Publication Date: 12th August 2025

  • DOI: 10.1186/s42269-025-01346-y

  • Contributors: Sourav Pal; Junaid Ahamed Laskar; Biprojit Bhowmick; Khokan Bera

  • Source: Crossref

  • Summary: This article explores the role of Helicobacter pylori in the pathogenesis of peptic ulcer disease and its impact on the gastric microbiome. It provides a comprehensive review of current therapeutic strategies and discusses innovative approaches, such as targeted microbiome manipulation and novel anti-H. pylori treatments, offering new directions for peptic ulcer management.

5. Therapeutic Potential of MicroRNAs in Neurological Disorders: Mechanisms, Biomarkers, and Emerging Therapeutic Strategies

  • Journal Article: Exploration of Neuroprotective Therapy

  • Publication Date: 14th July 2025

  • DOI: 10.37349/ent.2025.1004111

  • Contributors: Sourav Pal; Subhajit Mandal

  • Source: Crossref

  • Summary: This article examines the potential of microRNAs as biomarkers and therapeutic agents in neurological disorders. It explores the molecular mechanisms underlying microRNA regulation in the brain and their involvement in neurodegenerative diseases. The review also discusses the emerging therapeutic strategies that target microRNAs for neuroprotection, providing insight into the future of personalized treatment for neurological diseases.

Selvaraj Kunjiappan, Pharmacology, Best Researcher Award

Posted on by scizentox scizentoxLeave a Comment on Selvaraj Kunjiappan, Pharmacology, Best Researcher Award

Prof. Dr Selvaraj Kunjiappan: Professor at Sethu Institute of Technology, India

Dr. K. Selvaraj is a highly experienced researcher and academician in the field of Biotechnology, specializing in Biochemical Engineering. With more than 15 years of research and teaching experience, he is currently a Professor in the Department of Biotechnology at Kalasalingam Academy of Research and Education, Tamil Nadu, India. His research interests span the synthesis of novel drug-loaded nanoparticles for targeted therapies aimed at treating complex diseases such as cancer, diabetes, and neurological disorders. Dr. Selvaraj is committed to advancing the understanding of cellular signaling pathways, genetic network analysis, and the development of natural product-based drug delivery systems. Recognized as one of the world’s top 2% scientists, he has contributed significantly to scientific research, publishing extensively and working on multiple interdisciplinary projects.

Online Profiles

Google Scholar Profile

Citations & Metrics

Dr. Selvaraj’s scholarly impact is evident from his impressive citation metrics:

  • Total Citations: 2,588 (Previous: 2,399)

  • h-index: 29 (Previous: 27)

  • i10-index: 69 (Previous: 66)

These metrics reflect the significant influence of his research within his field, showcasing both the volume and the quality of his work over time. His growing h-index and i10-index are a testament to the enduring relevance and impact of his contributions in areas like drug delivery systems, cancer research, and computational biology.

Education

Dr. Selvaraj’s academic journey is marked by multiple post-doctoral fellowships and a solid educational foundation in Biotechnology and Chemical Engineering:

  • Post-Doctoral Research Fellow (Biological Sciences & Bioengineering), Indian Institute of Technology Roorkee, India (2024-2025).

  • Post-Doctoral Research Fellow (Biological Chemistry), University of Warsaw, Poland (2015).

  • Ph.D. in Chemical Engineering, Jadavpur University, Kolkata, India (2016).

  • M. Tech. in Industrial Biotechnology, Bharath Institute of Higher Education and Research, Chennai, India (2006).

  • B. Pharmacy, Tamil Nadu Dr. M.G.R. Medical University, Chennai, India (1999).

His academic background has been pivotal in shaping his interdisciplinary research in biotechnology, pharmacology, and drug delivery systems, further reinforcing his expertise in both theoretical and applied science.

Research Focus

Dr. Selvaraj’s research is centered on developing novel drug delivery systems using biodegradable nanoparticles to improve therapeutic outcomes for diseases such as cancer, diabetes, and Alzheimer’s. His work in drug-loaded nanoparticles aims at achieving better drug stability, bioavailability, and targeting efficiency. Additionally, he investigates the molecular mechanisms underlying various diseases by studying cellular signaling pathways and gene expression regulation. Another key area of his research involves discovering and utilizing bioactive molecules from natural sources for their potential in drug design and development, focusing on the molecular modeling of these compounds for therapeutic applications. Dr. Selvaraj’s innovative research continues to contribute toward advancements in targeted therapy, nanomedicine, and disease-specific drug discovery.

Experience

Dr. Selvaraj has an extensive academic and industrial experience that spans across multiple institutions and research environments:

  • Professor, Department of Biotechnology, Kalasalingam Academy of Research and Education, Tamil Nadu, India (2025-present).

  • Assistant Professor, Department of Biotechnology, Kalasalingam Academy of Research and Education, Tamil Nadu, India (2016-2025).

  • Lecturer, Department of Biotechnology, Rajalakshmi Engineering College, Chennai, India (2009-2012).

  • Lecturer, Department of Biotechnology, VMKV Engineering College, Salem, India (2006-2009).

  • Production Chemist, RPG Life Sciences Ltd. & Sun Pharma Ltd., Gujarat, India (1999-2004).

Throughout his career, Dr. Selvaraj has seamlessly integrated teaching and research, mentoring students and guiding several research projects at both undergraduate and postgraduate levels. His prior industry experience further complements his academic career, where he has worked in pharmaceutical production and quality control.

Research Timeline

Dr. Selvaraj’s career timeline highlights his significant contributions to research and development:

  • 2016: Completed Ph.D. in Chemical Engineering, focusing on drug delivery systems and nanoparticle synthesis.

  • 2015-2016: Postdoctoral research at the University of Warsaw, exploring biological chemistry and its applications in drug design.

  • 2020-2025: Ongoing research at Kalasalingam Academy of Research and Education on nanoparticle-based drug delivery, cancer therapy, and diabetes management.

  • 2024-2025: Postdoctoral research in Biological Sciences and Bioengineering at IIT Roorkee, focusing on interdisciplinary applications of biotechnology and bioengineering techniques.

Dr. Selvaraj’s research continues to evolve, with his current focus on the development of advanced nanomedicine and the exploration of cellular pathways in chronic diseases.

Awards & Honors

Dr. Selvaraj has received numerous prestigious awards throughout his career for his exceptional contributions to research and education:

  • Top 2% Scientists List (Stanford University & Elsevier, 2023 & 2024).

  • Erasmus Mundus Post-Doctoral Fellowship, University of Warsaw (2015).

  • INSA Visiting Scientist at IIT Roorkee (2020).

  • TEQIP Ph.D. Fellowship, Government of India (2013).
    These accolades reflect his outstanding research achievements and his dedication to advancing scientific knowledge in the field of biotechnology.

Recent Publication

Dr. Selvaraj has made significant contributions to scientific literature, with recent publications in high-impact journals:

  • Targeted Delivery of Thymoquinone-Encapsulated Polyethyleneimine/Poly (Lactic Acid) Nanoparticles into Breast Cancer Cells
    JS Pandi, P Pavadai, E Babkiewicz, T Panneerselvam, P Maszczyk, et al.
    2025
    This study investigates the targeted delivery of thymoquinone, a potent anticancer agent, encapsulated in nanoparticles to enhance the therapeutic efficacy in breast cancer treatment.

  • Computational Discovery of Plant-Derived Flavonoids as Potential Amyloid-β Fibril Disaggregating Agents for Alzheimer’s Disease
    UL Rakesh, GA Kumar, T Panneerselvam, P Pavadai, S Veerachamy, et al.
    Brain Disorders 18, 100233, 2025
    This research presents computational methods for identifying plant-derived flavonoids that could aid in Alzheimer’s treatment by disrupting amyloid-β fibrils.

  • Network Analysis and In Silico Molecular Modeling of Bioactive Compounds from Sida cordifolia Against NMDA Receptor
    CC Murali, S Kunjiappan, S Murugesan, SRK Pandian, T Kathiresan, et al.
    Journal of Computational Biophysics and Chemistry 24 (03), 307-318, 2025
    A comprehensive study using in silico methods to model bioactive compounds derived from Sida cordifolia and their potential for modulating the NMDA receptor, which plays a crucial role in neurodegenerative diseases.

  • Targeting the PI3K Pathway: Advancements and Achievements in Breast Cancer Therapy
    BGH Dinesh, SK Bandral, NM Sadashivappa, S Ganjipete, DN Ammunje, et al.
    Current Pharmaceutical Design, 2025
    This review provides an in-depth overview of the PI3K signaling pathway and its targeted therapies, particularly in the context of breast cancer treatment.

  • Elevated Temperature Enhances Task Performance by Improving Cognitive Abilities in Common Rudd (Scardinius erythrophthalmus)
    M Sysiak, E Babkiewicz, ML Zebrowski, K Rutkowska, S Kunjiappan, et al.
    Scientific Reports 15 (1), 7662, 2025
    A novel study exploring how temperature changes can impact cognitive performance in fish, with potential implications for behavioral neuroscience.

  • Pharmacokinetics and Brain Tumor Delivery Studies of Thymoquinone-Encapsulated Eudragit L100-Coated Solid-Lipid Nanoparticles
    J Senthamarai Pandi, P Pavadai, LM Sundar, M Sankaranarayanan, et al.
    Journal of Cluster Science 36 (1), 26, 2025
    This article investigates the pharmacokinetics and brain tumor-targeting potential of thymoquinone-loaded solid lipid nanoparticles, a promising delivery system for cancer therapy.

  • Surface Receptor-Targeted Protein-Based Nanocarriers for Drug Delivery: Advances in Cancer Therapy
    P Theivendren, P Pavadai, S Veerachamy, P Palanisamy, S Kunjiappan
    Nanotechnology 36 (12), 122003, 2025
    A review on the development of protein-based nanocarriers and their specific applications in targeting cancer cells for improved drug delivery.

  • Folic Acid-Conjugated Ferulic Acid-Entangled Single-Walled Carbon Nanotubes: A Targeted Therapeutic Approach for Effective Breast Cancer Treatment
    Journal of Drug Delivery Science and Technology 107111 (2), 1-22, 2025
    This study explores the use of folic acid-conjugated carbon nanotubes for targeted drug delivery in breast cancer, enhancing the effectiveness of treatment.

  • Cellulase from Halomonas elongata for Biofuel Application: Enzymatic Characterization and Inhibition Tolerance Investigation
    MD Narayanan A, Jeyaram K, Prabhu AA, Krishnan S, Kunjiappan S, Baskaran N
    Preparative Biochemistry and Biotechnology 1 (1), 1-20, 2025
    A detailed investigation into the enzymatic properties of cellulase from Halomonas elongata and its potential applications in biofuel production.

Brijesh Sukumaran, Pharmacology, Best Innovator Award

Posted on by scizentox scizentoxLeave a Comment on Brijesh Sukumaran, Pharmacology, Best Innovator Award

Dr. Brijesh Sukumaran: Assistant Professor at Sunandan Divatia School of Science, NMIMS (Deemed-to-be) University, Mumbai, India

Dr. Brijesh Sukumaran is an Assistant Professor at the Sunandan Divatia School of Science, NMIMS University, Mumbai, India, with over 15 years of experience in academia and research. He specializes in Microbiology, Immunology, Pharmacology, and Nano-drug delivery systems, particularly focused on the design and application of nanoparticles for drug delivery in chronic diseases like rheumatoid arthritis and psoriasis. With a Ph.D. in Applied Biology from The Foundation for Medical Research, Mumbai, Dr. Sukumaran is deeply involved in translational research and the development of therapeutic strategies leveraging both synthetic and natural compounds. He has published more than 30 research papers, contributed to several patents, and guided multiple Ph.D. and M.Sc. students.

Online Profiles

Education

Dr. Sukumaran completed his undergraduate degree in Microbiology (B.Sc.) from H.P.T. Arts & R.Y.K. Science College, Nasik, under the University of Pune in 1998. He continued his academic journey with a Master’s in Microbiology (M.Sc.) from the University of Pune in 2000. His doctoral research, completed in 2010 at The Foundation for Medical Research, Mumbai, focused on Applied Biology, exploring innovative approaches in drug delivery systems. This advanced education laid the foundation for his deep understanding of molecular biology, pharmacology, and nanotechnology.

Research Focus

Dr. Sukumaran’s research interests revolve around the design, formulation, and evaluation of advanced drug delivery systems, specifically targeting chronic inflammatory diseases such as rheumatoid arthritis and psoriasis. His work includes the use of solid lipid nanoparticles (SLNs), nanoemulsions, niosomes, and nanostructured lipid carriers (NLCs) for effective oral and topical drug delivery. A significant portion of his research also delves into exploring the therapeutic potential of plant-derived compounds in alleviating mental health conditions, such as anxiety and depression, by assessing their effects in both in vitro and animal models. His ultimate goal is to bridge the gap between laboratory research and clinical application through cutting-edge nanotechnology.

Experience

Dr. Sukumaran’s academic journey began at National Chemical Laboratory as a Project Assistant in 2000, where he first worked on biotechnological and pharmacological projects. After a brief transition to the pharmaceutical industry as an Area Sales Officer at Allergan India Ltd., he returned to research as a Research Assistant at The Foundation for Medical Research in 2009. There, he completed his postdoctoral work before transitioning into academia. Since June 2011, he has been an Assistant Professor at NMIMS University, where he has taught numerous undergraduate and postgraduate courses in Biomedical Science and Biological Sciences. He has also played a pivotal role in guiding Ph.D. and M.Sc. students, actively shaping the academic and research directions at the institution.

Research Timeline

  • 2000–2001: Worked as a Project Assistant at the National Chemical Laboratory, Pune.

  • 2009–2010: Completed a Post-doctoral Fellowship at The Foundation for Medical Research, Mumbai, focusing on advanced drug delivery systems.

  • 2011–Present: Assistant Professor at NMIMS University, Mumbai, leading various research projects on nano-drug delivery, pharmacology, and natural product therapeutics.

  • 2016–2023: Supervised and mentored multiple Ph.D. and M.Sc. students, several of whom have completed their theses on innovative drug delivery systems and pharmacological evaluations.

  • 2025: Ongoing research on nanocarriers for topical drug delivery in arthritis and psoriasis, with two Ph.D. theses currently submitted and pending defense.

Awards & Honors

Dr. Sukumaran received the Best Faculty award for the academic year 2018-2019 from the Sunandan Divatia School of Science, NMIMS University. This recognition was given in honor of his exceptional academic leadership, commitment to research excellence, and consistent contributions to improving the educational experience for students. His dedication to his students and innovative research has made him a respected figure at NMIMS University.

Recent Publication

Dr. Sukumaran’s research has led to over 30 publications in prestigious journals. Some of his most recent work includes:

1. Development of a Co-Loaded Microemulsion Composite Hydrogel for Enhanced Dermal Delivery of Cyclosporine A and Quercetin for Psoriasis Treatment

  • Journal: BioNanoScience

  • Date: September 2025

  • DOI: 10.1007/s12668-025-02107-x

  • Contributors: Ruchita Joshi, Brijesh Sukumaran

  • Summary: This article explores the development of a novel co-loaded microemulsion composite hydrogel aimed at enhancing the dermal delivery of Cyclosporine A (CsA) and Quercetin for psoriasis treatment. The hydrogel’s formulation is designed to offer improved stability and sustained release of the drugs, targeting the inflammatory pathways in psoriasis more effectively. The study demonstrates significant therapeutic potential in enhancing drug penetration into the skin while minimizing systemic toxicity.

2. Rethinking Arthritis: Exploring Its Types and Emerging Management Strategies

  • Journal: Inflammopharmacology

  • Date: July 1, 2025

  • DOI: 10.1007/s10787-025-01833-8

  • Contributors: Namrata Britto, Rajasekhar Reddy Alavala, S. Brijesh

  • Summary: This comprehensive review delves into various forms of arthritis, with a particular focus on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). It discusses the pathophysiology, challenges in treatment, and the latest advancements in both pharmacological and non-pharmacological management strategies. The paper also emphasizes emerging therapeutic targets, including biologics and personalized medicine, and provides insights into the evolving landscape of arthritis management.

3. Handbook of Coriander (Coriandrum Sativum)

  • Book Chapter: Handbook of Coriander (Coriandrum Sativum)

  • Year: 2022

  • DOI: 10.1201/9781003204626

  • Contributors: Mohamed Fawzy Ramadan

  • Summary: This book chapter discusses the pharmacological properties of coriander (Coriandrum sativum), focusing on its therapeutic potential in treating various diseases. Topics include coriander’s role as an anti-inflammatory, antimicrobial, and anti-cancer agent, alongside its ability to alleviate symptoms of metabolic disorders. The chapter explores both the biological activity of coriander’s active compounds and the potential mechanisms by which it exerts its effects.

4. Hyaluronic Acid-Coated Solid Lipid Nanoparticles Enhance Antirheumatic Activity and Reduce Toxicity of Methotrexate

  • Journal: Nanomedicine

  • Date: July 2022

  • DOI: 10.2217/nnm-2022-0009

  • Contributors: Yashika Mirchandani, Vandana B. Patravale, S. Brijesh

  • Summary: This research investigates the potential of hyaluronic acid-coated solid lipid nanoparticles (SLNs) to enhance the therapeutic efficacy and reduce the toxicity of methotrexate (MTX) in rheumatoid arthritis treatment. The study reports the successful formulation of MTX-loaded SLNs, which showed improved drug release and anti-rheumatic activity in animal models, while also significantly reducing systemic toxicity compared to free methotrexate.

5. Solid Lipid Nanoparticles for Hydrophilic Drugs

  • Journal: Journal of Controlled Release

  • Date: July 2021

  • DOI: 10.1016/j.jconrel.2021.05.032

  • Contributors: Yashika Mirchandani, Vandana B. Patravale, Brijesh S.

  • Summary: This article highlights the application of solid lipid nanoparticles (SLNs) for the delivery of hydrophilic drugs. It discusses various strategies to optimize the encapsulation efficiency, stability, and controlled release of hydrophilic bioactive molecules. The study provides insight into the potential of SLNs for enhancing the bioavailability of poorly soluble hydrophilic drugs, making them a promising solution for drug delivery systems.

Strength for the Best Innovator Award

1. Cutting-Edge Nanotechnology in Drug Delivery

Dr. Brijesh Sukumaran’s innovative research in the development and application of nano-drug delivery systems stands as a cornerstone of his work. His pioneering efforts in designing nanoparticles such as solid lipid nanoparticles (SLNs), nanoemulsions, and nanostructured lipid carriers (NLCs) for chronic diseases like rheumatoid arthritis and psoriasis have revolutionized the way therapeutics are delivered. These systems enhance drug bioavailability, improve targeting, and reduce toxicity, making him a leader in the field of nanomedicine.

2. Focus on Translational Research

Dr. Sukumaran’s commitment to bridging the gap between laboratory research and clinical application underscores his status as an innovator. His translational research approach is evident in his development of co-loaded microemulsion composite hydrogels for the targeted dermal delivery of Cyclosporine A and Quercetin. His work on integrating synthetic and natural compounds to treat chronic diseases like psoriasis not only advances scientific knowledge but also brings practical therapeutic solutions closer to patients.

3. Mentorship and Academic Leadership

With over 15 years of experience in academia, Dr. Sukumaran has been a trailblazer in educating and mentoring the next generation of researchers. His ability to guide Ph.D. and M.Sc. students, shape academic curriculum, and foster a collaborative research environment at NMIMS University is a testament to his leadership. Many of his students are contributing significantly to the field of drug delivery, creating a lasting impact on research and innovation.

4. Recognition and Awards for Excellence

Dr. Sukumaran’s dedication to research and education has been recognized by multiple honors, including the Best Faculty award from NMIMS University in 2018-2019. His ability to translate complex scientific concepts into impactful solutions for human health has earned him accolades from both his peers and students, reinforcing his reputation as a top innovator in biomedical sciences.

5. Multidisciplinary Research for Chronic Disease Management

Dr. Sukumaran’s multidisciplinary approach to addressing chronic diseases such as arthritis and psoriasis reflects his innovative mindset. His recent publication on emerging arthritis management strategies and the development of hyaluronic acid-coated solid lipid nanoparticles for enhanced methotrexate delivery highlights his contributions not just to pharmacology, but also to material science, immunology, and molecular biology. His innovative work in chronic disease management holds the potential to significantly alter therapeutic strategies and improve patient outcomes worldwide.

Nazzareno Cannella, Pharmacology, Best Researcher Award

Posted on by scizentox scizentoxLeave a Comment on Nazzareno Cannella, Pharmacology, Best Researcher Award

Professor Nazzareno Cannella: Associate Professor at University of Camerino, Italy

Dr. Nazzareno Cannella is an accomplished Associate Professor of Pharmacology at the University of Camerino, Italy, with a strong focus on neuropsychopharmacology. Over the years, his research has explored the neurobiology of motivated behaviors and reward systems, particularly in relation to substance use disorders (SUD) involving alcohol, psychostimulants, nicotine, and opioids. Dr. Cannella’s work also addresses the co-occurrence of psychiatric disorders such as anxiety, PTSD, and depression, which often co-appear with SUDs. His multifaceted research integrates a variety of cutting-edge techniques, including in-vivo behavioral models, pharmacology, neuroimaging (MRI, PET), and genetic manipulation. He seeks to advance personalized and translational medicine in addiction research by exploring individualized treatment responses and the identification of biomarkers for SUDs.

Online Profiles

Dr. Cannella maintains an extensive academic presence online. His work can be found in various scientific databases and repositories:

  • Scopus Author ID: 24079967600

  • ORCID: 0000-0002-2891-8679
    His complete list of over 60 publications, which includes groundbreaking studies in addiction research, is accessible on his NCBI Bibliography. This includes his collaborative work on preclinical models and his exploration of neurobiological mechanisms underlying addiction.

  • 1,483 Citations from 1,086 Documents

  • 62 Documents published

  • h-index of 23

Education

Dr. Cannella’s academic journey began with a Master of Science in Biology from the University of Camerino in 2005. He then pursued his PhD in Neuropsychopharmacology at the same institution, earning his degree in 2009. His dissertation, under the supervision of Dr. Roberto Ciccocioppo, focused on the neurobiology of addiction and pharmacological interventions. To expand his expertise, he spent a year as a visiting scholar at Stanford University School of Medicine, where he worked with Dr. Luis de Lecea. Dr. Cannella then honed his research skills through postdoctoral fellowships at leading European institutions, including the Central Institute of Mental Health in Mannheim, Germany, and the Neurocentre Magendie in Bordeaux, France.

Research Focus

Dr. Cannella’s research focuses on the neurobiological underpinnings of substance use disorders (SUD) and their psychiatric comorbidities. His primary interest lies in understanding the reward circuitry in the brain, which plays a crucial role in addiction and motivated behaviors. He is especially concerned with how these systems interact with mental health conditions like anxiety, depression, and impulsivity. In addition to the basic neurobiology of addiction, his work spans treatment development, personalized medicine, and translational medicine, aiming to design more effective therapies for addiction. Dr. Cannella also investigates individual variability in response to treatment, with a goal of improving the precision of addiction therapies. His research integrates advanced techniques such as behavioral rodent models, neuroimaging, pharmacological interventions, and molecular biology.

Experience

Dr. Cannella has held various academic positions throughout his career, contributing significantly to the fields of pharmacology and neuropsychopharmacology. He is currently an Associate Professor of Pharmacology at the University of Camerino, a position he has held since 2023. Prior to this, he served as an Assistant Professor from 2020 to 2022. His long-standing association with the Central Institute of Mental Health in Mannheim, Germany, as a Guest Scientist since 2017 has allowed him to collaborate on numerous international research projects. Dr. Cannella also gained valuable experience as a Research Assistant Professor and Research Associate at the University of Camerino, Italy, where he has played a pivotal role in advancing both the academic and research profiles of the institution. His work has consistently been supported by various competitive research grants, allowing him to lead multiple interdisciplinary teams working on addiction-related projects.

Research Timeline

Dr. Cannella’s research timeline begins with his PhD in 2009, where his foundational work on the neurobiology of addiction set the stage for his future studies. From 2010 to 2016, he honed his skills through postdoctoral training in Germany and France, focusing on neuropharmacology and behavioral neuroscience. In 2016, he became a Research Associate at the University of Camerino, where he soon expanded his research interests to explore individualized vulnerability to addiction. His significant work on SUD biomarkers, genetic vulnerability, and personalized medicine began to take shape during his tenure as a Research Assistant Professor from 2019 to 2020. In 2023, he advanced to the role of Associate Professor, where his research is now funded by prestigious grants such as the NIH/NIAAA and the Hetzler Foundation, ensuring that his work on addiction continues to be at the forefront of scientific discovery.

Awards & Honors

Dr. Cannella has received various awards and honors throughout his career, including multiple competitive research grants and recognition from leading scientific societies. He is an active member of prestigious organizations such as the Italian Society of Neuroscience, the Federation of European Neuroscience Societies, and the European Behavioral Pharmacology Society. His research has been frequently cited and recommended by expert panels, including F1000 and NIDA’s Blog. Additionally, his work on personalized medicine and addiction has garnered attention in both academic and clinical settings, making him a leading figure in addiction research.

Top-Noted Publication

Dr. Cannella’s top-noted publication is a 2024 study in Neuropharmacology on Cebranopadol, a novel opioid agonist. This study demonstrated Cebranopadol’s potential in treating opioid use disorder with a low risk of abuse, a significant advancement in the search for safer alternatives to traditional opioid therapies. The paper, titled “Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy”, highlights Dr. Cannella’s commitment to developing effective, less harmful treatments for addiction. His work on the molecular mechanisms underlying addiction continues to influence drug development strategies for a range of substance use disorders.

  • Predicting individual treatment response in alcohol use disorders: a reverse translational proof-of-concept study
    Translational Psychiatry | Published: June 24, 2025
    DOI: 10.1038/s41398-025-03431-2
    This study explores the reverse translational approach to predicting personalized treatment responses in alcohol use disorder (AUD), offering valuable insights into the future of individualized treatments for addiction.

  • Genome-wide association study reveals multiple loci for nociception and opioid consumption behaviors associated with heroin vulnerability in outbred rats
    Molecular Psychiatry | Published: February 25, 2025
    DOI: 10.1038/s41380-025-02922-4
    This research identifies genetic loci related to nociception and opioid consumption behaviors, contributing to our understanding of heroin addiction and individual vulnerability.

  • Pharmacological Mechanism and Drug Research Prospects of Ginsenoside Rb1 as an Antidepressant
    Antioxidants (Basel, Switzerland) | Published: February 19, 2025
    DOI: 10.3390/antiox14020238
    This article reviews the pharmacological properties of Ginsenoside Rb1, examining its potential as an antidepressant, with a focus on its therapeutic prospects in neuropsychiatric disorders.

  • Distinct Behavioral Profiles and Neuronal Correlates of Heroin Vulnerability Versus Resiliency in a Multi-Symptomatic Model of Heroin Use Disorder in Rats
    The American Journal of Psychiatry | Published: January 15, 2025
    DOI: 10.1176/appi.ajp.20230623
    This study distinguishes between behavioral and neuronal correlates of vulnerability versus resiliency in heroin use disorder, providing critical insights into potential therapeutic strategies.

  • Cebranopadol, a novel long-acting opioid agonist with low abuse liability, to treat opioid use disorder: Preclinical evidence of efficacy
    Neuropharmacology | Published: October 2024
    DOI: 10.1016/j.neuropharm.2024.110048
    This publication presents preclinical evidence for the efficacy of Cebranopadol, a novel opioid agonist with a promising profile for treating opioid use disorder without significant abuse liability.

Michel De Waard, Pharmacology, Innovative Researcher Award

Posted on by scizentoxLeave a Comment on Michel De Waard, Pharmacology, Innovative Researcher Award

Dr. Michel De Waard: Teal leader – Emeritus science director at INSERM UMR1087 – l’institut du thorax, France

Michel De Waard is a Senior Research Director at INSERM with extensive expertise in ion channel research, peptide engineering, and drug discovery. He has led groundbreaking studies in cardiopathies and cardiovascular safety, with a particular focus on translating natural peptide libraries into therapeutic applications. Michel has a rich academic background, holding degrees in Physiology, Biochemistry, and Neurosciences, and has made significant contributions to both academia and industry, including founding Smartox Biotechnology.

Online Profiles

  • ORCID Profile
  • Citations: 1,153 citations across 964 documents
  • h-index: 20
  • Documents: 93

Education
Michel De Waard completed his undergraduate and graduate studies at the University Louis Pasteur in Strasbourg, France, where he earned a B.A. in Physiology, an M.S. in both Physiology and Biochemistry, and a PhD in Neurosciences from the University Aix-Marseille I. He further honed his expertise through postdoctoral research in hyperbaric physiology, neurobiology, and ion channel research at various prestigious institutions including the Howard Hughes Medical Institute in the USA.

Research Focus
Michel’s research focuses on ion channels, particularly in the context of cardiac diseases and pharmacology. He investigates the structure-function relationships of voltage-dependent ion channels, peptide engineering from animal venoms, and the development of peptide-based therapies for cardiovascular safety. His work spans cell biology, biophysics, and the preclinical development of new drugs, with an emphasis on translating basic science into clinical applications.

Experience
Michel has held numerous leadership positions at INSERM, from Head of Research Teams to Director of Laboratories. He has guided large research teams, including his current leadership of the “Ion Channels and Cardiopathies” team at the Institut du Thorax in Nantes, France. Michel’s experience extends to managing technology transfer and fostering academic-industry collaborations, including his role as founder of Smartox Biotechnology, a company focused on drug discovery from natural peptides.

Research Timeline
Michel De Waard’s research career spans over three decades, beginning with his early studies on ion channels and physiology in the 1980s. From his postdoctoral work at the Howard Hughes Medical Institute to his current role at INSERM, Michel has consistently advanced the understanding of ion channels and their role in cardiac diseases. His career has been marked by continuous leadership, moving from group leader roles to his current position heading a major research team in Nantes.

Awards & Honors
Michel De Waard has received numerous accolades throughout his career, including the Servier Young Investigator Award and recognition for the best posters at major international scientific meetings. He was also honored as the laureate of the innovative company prize from the Rotary Club and the Chamber of Commerce in Grenoble for founding Smartox Biotechnology.

Top-Noted Publication

Michel De Waard has authored nearly 300 peer-reviewed publications. Some of his most notable works focus on ion channel mechanisms and their implications in drug development. His research on the SAR (structure-activity relationship) of peptides from animal venoms and their applications in cardiac pharmacology stands out as a key contribution to the field.

Immunomodulatory effects of epiphytic Loranthus micranthus leaf extracts collected from two host plants: Psidium guajava and Parkia biglobosa

  • Journal: BMC Complementary Medicine and Therapies
  • Publication Year: 2024
  • DOI: 10.1186/S12906-023-04282-4
  • WOSUID: WOS:001135380500005
  • Contributors: Idoko, Ngozi Dorathy; Chukwuma, Ifeoma Felicia; Nworah, Florence Nkechi; Mba, Sopuruchukwu Elizabeth; Joshua, Parker Elijah; Nwodo, Okwesilieze Fred Chiletugo; Abusudah, Wafaa Fouzi; Almohmadi, Najlaa Hamed; de Waard, Michel.
  • Focus: This article investigates the immunomodulatory effects of Loranthus micranthus leaf extracts from two different host plants, Psidium guajava and Parkia biglobosa.

Structure–Function Relationship of a Novel MTX-like Peptide (MTX1) Isolated and Characterized from the Venom of the Scorpion Maurus palmatus

  • Journal: International Journal of Molecular Sciences
  • Publication Year: 2024 (September 28)
  • DOI: 10.3390/ijms251910472
  • Contributors: Rym ElFessi; Oussema Khamessi; Michel De Waard; Najet Srairi-Abid; Kais Ghedira; Riadh Marrouchi; Riadh Kharrat.
  • Focus: The article explores the structure-function relationship of MTX1, a peptide isolated from Maurus palmatus venom, emphasizing its potential in therapeutic applications.

Effects of a High Trans Fatty Acid Diet on Kidney-, Liver-, and Heart-Associated Diseases in a Rabbit Model

  • Journal: Metabolites
  • Publication Year: 2024 (August)
  • DOI: 10.3390/metabo14080442
  • Contributors: Hammad Ismail; Zaryab Mubashar; Hajra Khan; Zeenat Naveed; Erum Dilshad; Muhammad Zeeshan Bhatti; Sadaf Anwaar; Samreen Saleem; Sabba Mehmood; Abdur Rahman, et al.
  • Focus: This study evaluates the impact of a high trans fatty acid diet on diseases associated with the kidney, liver, and heart, using a rabbit model.

Rattlesnake Crotalphine Analgesic Active on Tetrodotoxin-Sensitive Na+ Current in Mouse Dorsal Root Ganglion Neurons

  • Journal: Toxins
  • Publication Year: 2024 (August 15)
  • DOI: 10.3390/toxins16080359
  • Contributors: Aurélie Antunes; Philippe Robin; Gilles Mourier; Rémy Béroud; Michel De Waard; Denis Servent; Evelyne Benoit.
  • Focus: This research discusses the analgesic effects of Crotalphine, derived from rattlesnake venom, on tetrodotoxin-sensitive Na+ currents in neurons, highlighting its therapeutic potential.

A Need for Exhaustive and Standardized Characterization of Ion Channels Activity. The Case of K<sub>V</sub>11.1

  • Journal: Frontiers in Physiology
  • Publication Year: 2023
  • DOI: 10.3389/FPHYS.2023.1132533
  • WOSUID: WOS:000940510500001
  • Contributors: Alameh, Malak; Oliveira-Mendes, Barbara Ribeiro; Kyndt, Florence; Rivron, Jordan; Denjoy, Isabelle; Lesage, Florian; Schott, Jean-Jacques; De Waard, Michel; Loussouarn, Gildas.
  • Focus: The article emphasizes the importance of standardized and thorough characterization of ion channels, specifically the K<sub>V</sub>11.1 channel, to advance scientific understanding and therapeutic development.
“Strength for the Innovative Researcher Award” based on Dr. Michel De Waard’s work and contributions:

  1. Ion Channel Research in Cardiovascular Diseases
    Explore Dr. De Waard’s groundbreaking research on the structure-function relationships of ion channels, particularly in cardiac pathophysiology. His work in understanding ion channel dysfunction in heart diseases has led to novel therapeutic insights, advancing both basic science and clinical approaches to cardiovascular safety.

  2. Peptide Engineering for Therapeutic Applications
    Focus on Dr. De Waard’s pioneering efforts in peptide engineering from animal venoms and their use in drug discovery. By utilizing natural peptide libraries, his research has paved the way for the development of peptide-based therapies targeting ion channels, offering new therapeutic strategies for various diseases.

  3. Innovative Drug Discovery and Translational Research
    Discuss Dr. De Waard’s impact in translating academic research into clinical applications, specifically through his leadership in the development of new drugs. His work, including the founding of Smartox Biotechnology, has bridged the gap between academic research and industry innovation, particularly in ion channel-targeted therapies.

  4. Standardization of Ion Channel Characterization
    Highlight Dr. De Waard’s advocacy for standardized and exhaustive characterization of ion channels, focusing on specific channels like K<sub>V</sub>11.1. This work is crucial for advancing both scientific understanding and the development of more reliable and targeted therapeutic interventions for ion channel-related diseases.

  5. Collaborative Efforts in Academic and Industry Partnerships
    Examine Dr. De Waard’s role in fostering collaboration between academia and industry. His leadership in INSERM and Smartox Biotechnology demonstrates how partnerships can drive innovation in the biomedical field, translating cutting-edge research into real-world medical solutions.

These topics reflect Dr. De Waard’s diverse and innovative contributions to the fields of ion channel research, peptide engineering, and drug development, which have had significant implications for both basic science and clinical applications.

Xiaofeng Wu, Pharmacology, Best Researcher Award

Posted on by scizentoxLeave a Comment on Xiaofeng Wu, Pharmacology, Best Researcher Award

Dr. Xiaofeng Wu: Senior Scientist at Pharmacokinetics, Dynamics and Metabolism at Pfizer Inc, United States

Dr. Xiaofeng Wu is a Senior Scientist at Pfizer Inc., where he works in the Medicine Design division specializing in pharmacokinetics, pharmacodynamics, and metabolism. With a passion for advancing healthcare research, Dr. Wu has focused much of his career on utilizing proteomics and phosphoproteomics to understand complex disease mechanisms, discover novel biomarkers, and monitor drug efficacy. His research has made significant contributions to the field of clinical proteomics, particularly in relation to extracellular vesicles (EVs) derived from human biofluids. Dr. Wu earned his Ph.D. in Analytical Chemistry from Purdue University, where he worked on innovative techniques in mass spectrometry, establishing himself as a leading researcher in translational proteomics.

Online Profiles:

Google Scholar Profile

ORCID Profile

Dr. Wu’s publications have garnered significant attention in the scientific community, with a citation count of 386 and an h-index of 9 (indicating a strong influence in his field). His i10-index stands at 9, showing the sustained impact of his published work.

Education:

Dr. Wu’s academic journey began with a Bachelor of Science in Chemistry from Peking University, where he developed a strong foundation in analytical chemistry. He later pursued a Ph.D. in Analytical Chemistry at Purdue University, under the mentorship of Prof. W. Andy Tao. At Purdue, he focused on the cutting-edge use of mass spectrometry in the study of extracellular vesicles (EVs) for translational research, including drug metabolism, disease biomarkers, and therapeutic monitoring. His doctoral research provided insights into new proteomic techniques that hold promise for improving clinical practices in oncology, cardiovascular diseases, and metabolic disorders.

Research Focus:

Dr. Wu’s research is primarily focused on extracellular vesicles (EVs), tiny particles secreted by cells that carry proteins, lipids, and RNA. He has pioneered methods to isolate and analyze EVs from human biofluids like plasma, urine, and tissue, exploring their potential as sources for disease biomarkers and therapeutic targets. His work is especially notable in the areas of cancer diagnostics, drug response monitoring, and precision medicine. Using advanced mass spectrometry techniques, Dr. Wu’s research aims to provide deeper insights into protein and phosphoprotein signaling in various diseases, enabling faster and more accurate disease diagnosis and treatment efficacy evaluation. He is also dedicated to developing novel, high-throughput analytical methods to make these approaches more practical for clinical settings.

Experience:

Dr. Wu’s professional experience includes his current role as Senior Scientist at Pfizer Inc., where he applies his expertise in pharmacokinetics and mass spectrometry to advance drug development. He plays a pivotal role in the characterization of drug metabolism and efficacy through the analysis of extracellular vesicles. Before joining Pfizer, Dr. Wu earned his Ph.D. at Purdue University, where he worked on multiple collaborative research projects with prominent institutions such as St. Jude Children’s Research Hospital, Merck & Co., and Indiana University Health. Throughout his career, Dr. Wu has co-authored over 20 publications, many in top-tier journals, and has been invited to present his work at international conferences. His multidisciplinary collaborations have also extended to various sectors, including pharmaceutical companies and academic research labs, making him a recognized leader in his field.

Research Timeline:

  • 2022 – Present: Senior Scientist at Pfizer Inc., focusing on pharmacokinetics, pharmacodynamics, and metabolism in drug development. Dr. Wu is heavily involved in the analysis of protein biomarkers in extracellular vesicles for therapeutic assessment.
  • 2016 – 2022: Ph.D. in Analytical Chemistry from Purdue University, under the mentorship of Prof. W. Andy Tao. His dissertation focused on developing new methods for proteomic analysis of extracellular vesicles and their use in clinical applications.
  • 2012 – 2016: Bachelor of Science in Chemistry, Peking University. Dr. Wu’s early research explored the basics of analytical chemistry and mass spectrometry, laying the foundation for his future work in proteomics.

Awards & Honors:

Dr. Wu has received numerous honors and accolades throughout his career. He has been invited to speak at major scientific conferences, including the American Society of Mass Spectrometry and the US HUPO Conference, where he shared his research on EV proteomics and biomarker discovery. Additionally, he serves as a guest reviewer for high-impact journals such as Journal of Proteome Research, Molecular and Cellular Proteomics, and Proteomics – Clinical Applications. He is also on the editorial boards of several scientific journals, reflecting his expertise and influence in the field of analytical chemistry and proteomics. Dr. Wu’s pioneering work on the development of high-throughput methods for analyzing EVs has also been recognized with publications in top-tier journals.

Top-Noted Publication:

Wu, X., Liu, Y.-K., Iliuk, A. B., Tao, W. A. (2023). One-Pot Analytical Pipeline for Efficient and Sensitive Proteomic Analysis of Extracellular Vesicles. Journal of Proteome Research, 22(10), 3301-3310. This publication showcases Dr. Wu’s innovative work on a novel one-pot method for isolating and analyzing extracellular vesicles, providing a fast and efficient approach for clinical proteomics. The paper is highly regarded in the scientific community and has contributed significantly to the advancement of translational research in proteomics.

  • “Mass spectrometry-based phosphoproteomics in clinical applications”
    X Wu, YK Liu, AB Iliuk, WA Tao, TrAC Trends in Analytical Chemistry, 163, 117066 (2023).
    This influential paper discusses the role of mass spectrometry in phosphoproteomics, focusing on its clinical applications, including monitoring disease progression and therapeutic responses through protein phosphorylation.
    Citations: 9
  • “In-depth discovery of protein lactylation in hepatocellular carcinoma”
    X Wu, Proteomics, 23(9), 2300003 (2023).
    This study provides a comprehensive analysis of protein lactylation in hepatocellular carcinoma, uncovering new insights into the post-translational modifications that could serve as biomarkers for liver cancer diagnosis.
    Citations: 9
  • “All-in-One strategy for downstream molecular profiling of tumor-derived exosomes”
    S Wang, Y He, J Lu, Y Wang, X Wu, G Yan, X Fang, B Liu, ACS Applied Materials & Interfaces, 14(32), 36341–36352 (2022).
    This paper presents a robust strategy for profiling tumor-derived exosomes, offering a powerful tool for molecular cancer diagnostics and therapeutic monitoring.
    Citations: 9
  • “One-Pot Analytical Pipeline for Efficient and Sensitive Proteomic Analysis of Extracellular Vesicles”
    YK Liu, X Wu, M Hadisurya, L Li, H Kaimakliotis, A Iliuk, WA Tao, Journal of Proteome Research, 22(10), 3301–3310 (2023).
    This publication highlights the development of an efficient and sensitive one-pot analytical pipeline for EV proteomics, improving the speed and accuracy of extracellular vesicle analysis in clinical settings.
    Citations: 3
  • “Isolation and identification of plasma extracellular vesicles protein biomarkers”
    MV Lihon, M Hadisurya, X Wu, A Iliuk, WA Tao, Cancer Systems and Integrative Biology, 207–217 (2023).
    This study focuses on isolating and identifying plasma EV protein biomarkers, providing significant contributions to cancer biomarker discovery for early detection and monitoring.
    Citations: 3
  • “Monitoring drug metabolic pathways through extracellular vesicles in mouse plasma”
    X Wu, M Quan, M Hadisurya, J Hu, YK Liu, Y Zhuang, L Li, AB Iliuk, PNAS Nexus, 3(2), pgae023 (2024).
    This paper explores the use of EVs in monitoring drug metabolism pathways in mouse plasma, further bridging the gap between clinical research and therapeutic drug development.
    Citations: 2